Display options
Cite
Romee R, Leong JW, Fehniger TA. Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica (Cairo). 2014;2014:205796doi: 10.1155/2014/205796.
Romee, R., Leong, J. W., & Fehniger, T. A. (2014). Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica, 2014205796. https://doi.org/10.1155/2014/205796
Romee, Rizwan, et al. "Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer." Scientifica vol. 2014 (2014): 205796. doi: https://doi.org/10.1155/2014/205796
Romee R, Leong JW, Fehniger TA. Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica (Cairo). 2014;2014:205796. doi: 10.1155/2014/205796. Epub 2014 Jun 25. PMID: 25054077; PMCID: PMC4099226.
Copy Download .nbib Format: NLM
Share it on

Scientifica (Cairo). 2014;2014:205796. doi: 10.1155/2014/205796. Epub 2014 Jun 25.

Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer.

Scientifica

Rizwan Romee, Jeffrey W Leong, Todd A Fehniger

Affiliations

  1. Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.

PMID: 25054077 PMCID: PMC4099226 DOI: 10.1155/2014/205796

Abstract

Natural killer (NK) cells are innate lymphoid cells important for host defense against pathogens and mediate antitumor immunity. Cytokine receptors transduce important signals that regulate proliferation, survival, activation status, and trigger effector functions. Here, we review the roles of major cytokines that regulate human NK cell development, survival, and function, including IL-2, IL-12, IL-15, IL-18, and IL-21, and their translation to the clinic as immunotherapy agents. We highlight a recent development in NK cell biology, the identification of innate NK cell memory, and focus on cytokine-induced memory-like (CIML) NK cells that result from a brief, combined activation with IL-12, IL-15, and IL-18. This activation results in long lived NK cells that exhibit enhanced functionality when they encounter a secondary stimulation and provides a new approach to enable NK cells for enhanced responsiveness to infection and cancer. An improved understanding of the cellular and molecular aspects of cytokine-cytokine receptor signals has led to a resurgence of interest in the clinical use of cytokines that sustain and/or activate NK cell antitumor potential. In the future, such strategies will be combined with negative regulatory signal blockade and enhanced recognition to comprehensively enhance NK cells for immunotherapy.

References

  1. J Clin Oncol. 2012 Sep 20;30(27):3396-401 - PubMed
  2. Nat Immunol. 2008 May;9(5):495-502 - PubMed
  3. Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):728-32 - PubMed
  4. J Immunol. 2006 Nov 1;177(9):6072-80 - PubMed
  5. Lancet. 2000 Nov 25;356(9244):1795-9 - PubMed
  6. Blood. 2008 May 1;111(9):4723-30 - PubMed
  7. Blood. 2010 Jun 3;115(22):4377-83 - PubMed
  8. Immunity. 1998 Mar;8(3):383-90 - PubMed
  9. Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9166-71 - PubMed
  10. Clin Cancer Res. 1999 Jan;5(1):9-16 - PubMed
  11. J Exp Med. 1992 Mar 1;175(3):779-88 - PubMed
  12. J Biomed Biotechnol. 2011;2011:379123 - PubMed
  13. Hum Immunol. 2011 Nov;72(11):1013-7 - PubMed
  14. J Exp Med. 1990 May 1;171(5):1509-26 - PubMed
  15. Immunity. 2012 Jul 27;37(1):171-86 - PubMed
  16. Nat Immunol. 2011 Jan;12(1):21-7 - PubMed
  17. Immunobiology. 2008;213(3-4):271-83 - PubMed
  18. PLoS One. 2011;6(11):e27351 - PubMed
  19. Clin Immunol. 2006 Jan;118(1):1-10 - PubMed
  20. Blood. 2000 May 15;95(10):3183-90 - PubMed
  21. Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18324-9 - PubMed
  22. Blood. 2006 Sep 1;108(5):1571-9 - PubMed
  23. Blood. 1997 Oct 1;90(7):2541-8 - PubMed
  24. PLoS One. 2012;7(1):e30264 - PubMed
  25. Immunity. 2010 Aug 27;33(2):153-65 - PubMed
  26. Nat Rev Immunol. 2008 Sep;8(9):713-25 - PubMed
  27. Immunol Rev. 2006 Dec;214:92-105 - PubMed
  28. Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1915-9 - PubMed
  29. Clin Cancer Res. 1998 Jan;4(1):75-85 - PubMed
  30. J Exp Med. 2012 Dec 17;209(13):2351-65 - PubMed
  31. J Clin Invest. 2002 Oct;110(7):983-92 - PubMed
  32. Leukemia. 2004 Nov;18(11):1835-8 - PubMed
  33. Nat Immunol. 2006 May;7(5):507-16 - PubMed
  34. J Clin Invest. 1998 Mar 15;101(6):1373-8 - PubMed
  35. Immunol Rev. 2006 Dec;214:56-72 - PubMed
  36. J Immunol. 2007 Sep 15;179(6):3596-603 - PubMed
  37. Blood. 2007 May 15;109(10):4135-42 - PubMed
  38. Blood. 2008 Mar 15;111(6):3155-62 - PubMed
  39. Curr Opin Immunol. 2009 Oct;21(5):525-30 - PubMed
  40. Biol Blood Marrow Transplant. 2010 Aug;16(8):1107-14 - PubMed
  41. J Immunol. 2007 Jul 1;179(1):89-94 - PubMed
  42. Cancer J Sci Am. 1997 Dec;3 Suppl 1:S121-7 - PubMed
  43. Nature. 2005 Aug 4;436(7051):709-13 - PubMed
  44. J Exp Med. 1993 Oct 1;178(4):1223-30 - PubMed
  45. J Immunol. 2000 Aug 1;165(3):1307-13 - PubMed
  46. N Engl J Med. 2012 Aug 30;367(9):805-16 - PubMed
  47. Cytokine Growth Factor Rev. 2002 Apr;13(2):169-83 - PubMed
  48. Blood. 2008 Aug 1;112(3):461-9 - PubMed
  49. J Immunol. 1994 Aug 15;153(4):1697-706 - PubMed
  50. J Immunol. 2004 Jul 1;173(1):657-65 - PubMed
  51. J Exp Med. 2013 Jun 3;210(6):1167-78 - PubMed
  52. Clin Cancer Res. 2007 Nov 1;13(21):6419-28 - PubMed
  53. Blood. 2010 Jan 14;115(2):274-81 - PubMed
  54. J Exp Med. 1987 Oct 1;166(4):1055-69 - PubMed
  55. Hematology Am Soc Hematol Educ Program. 2013;2013:234-46 - PubMed
  56. Biol Blood Marrow Transplant. 2012 Apr;18(4):536-45 - PubMed
  57. Blood. 2007 Jul 15;110(2):578-86 - PubMed
  58. Adv Immunol. 2009;101:27-79 - PubMed
  59. Nat Rev Immunol. 2006 Aug;6(8):595-601 - PubMed
  60. Cell. 2010 Sep 17;142(6):847-56 - PubMed
  61. J Exp Med. 1989 Sep 1;170(3):827-45 - PubMed
  62. J Exp Med. 2011 Feb 14;208(2):357-68 - PubMed
  63. Annu Rev Immunol. 2005;23:225-74 - PubMed
  64. Br J Cancer. 2012 Feb 28;106(5):793-8 - PubMed
  65. Blood. 2001 Jan 1;97(1):14-32 - PubMed
  66. Blood. 2008 Aug 1;112(3):914-5 - PubMed
  67. Science. 2002 Mar 15;295(5562):2097-100 - PubMed
  68. Immunity. 2007 Jun;26(6):798-811 - PubMed
  69. Cancer Immunol Immunother. 1998 Aug;46(6):318-26 - PubMed
  70. Clin Cancer Res. 1997 Mar;3(3):409-17 - PubMed
  71. Blood Cells Mol Dis. 2004 Nov-Dec;33(3):261-6 - PubMed
  72. J Clin Oncol. 2005 Dec 1;23(34):8835-44 - PubMed
  73. Annu Rev Immunol. 1998;16:495-521 - PubMed
  74. Annu Rev Immunol. 2002;20:323-70 - PubMed
  75. Clin Cancer Res. 2004 Aug 1;10(15):5027-37 - PubMed
  76. Trends Immunol. 2011 Aug;32(8):364-72 - PubMed
  77. Int J Cancer. 1975 Aug 15;16(2):216-29 - PubMed
  78. Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11439-44 - PubMed
  79. J Exp Med. 2006 Apr 17;203(4):1033-43 - PubMed
  80. Nat Rev Immunol. 2007 May;7(5):329-39 - PubMed
  81. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6056-63 - PubMed
  82. J Clin Oncol. 1991 Dec;9(12):2110-9 - PubMed
  83. J Exp Med. 1990 May 1;171(5):1527-33 - PubMed
  84. Blood. 2003 Apr 15;101(8):3052-7 - PubMed
  85. Biol Blood Marrow Transplant. 2012 Jan;18(1 Suppl):S2-7 - PubMed
  86. Trends Immunol. 2001 Nov;22(11):633-40 - PubMed
  87. Blood. 2008 Aug 1;112(3):699-707 - PubMed
  88. Adv Immunol. 2005;86:209-39 - PubMed
  89. Curr Opin Immunol. 2003 Jun;15(3):308-14 - PubMed
  90. J Immunol. 1998 Oct 1;161(7):3400-7 - PubMed
  91. J Immunol. 2009 May 15;182(10):6267-77 - PubMed
  92. Arthritis Res Ther. 2004;6(1):8-14 - PubMed
  93. Annu Rev Immunol. 2006;24:657-79 - PubMed
  94. Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4265-73 - PubMed
  95. Blood. 2008 Apr 15;111(8):4173-83 - PubMed
  96. J Clin Invest. 1993 Jan;91(1):123-32 - PubMed
  97. EMBO Rep. 2009 Oct;10(10):1103-10 - PubMed
  98. Blood. 2012 Mar 15;119(11):2665-74 - PubMed
  99. Blood. 2012 Dec 6;120(24):4751-60 - PubMed
  100. Nat Rev Immunol. 2003 May;3(5):413-25 - PubMed
  101. J Immunol. 2008 Aug 1;181(3):1627-31 - PubMed
  102. Clin Cancer Res. 2007 Jun 15;13(12):3630-6 - PubMed
  103. J Clin Oncol. 2010 Feb 20;28(6):955-9 - PubMed
  104. Immunol Rev. 2008 Aug;224:85-97 - PubMed
  105. Cytokine. 2011 Dec;56(3):804-10 - PubMed
  106. Blood. 2009 Sep 17;114(12):2417-26 - PubMed
  107. Blood. 2010 Mar 18;115(11):2167-76 - PubMed
  108. Blood. 2013 Apr 4;121(14):2669-77 - PubMed
  109. Nat Immunol. 2010 Apr;11(4):321-7 - PubMed
  110. Eur J Immunol. 1992 Jan;22(1):1-6 - PubMed
  111. Trends Immunol. 2010 Jun;31(6):220-7 - PubMed
  112. Immunity. 2007 Apr;26(4):503-17 - PubMed
  113. Blood. 1994 May 1;83(9):2594-601 - PubMed
  114. Nat Rev Immunol. 2007 Sep;7(9):703-14 - PubMed
  115. J Immunol. 2009 Sep 15;183(6):3598-607 - PubMed
  116. J Immunother. 2013 Jul-Aug;36(6):331-41 - PubMed
  117. J Immunol. 2007 Apr 15;178(8):4764-70 - PubMed
  118. J Immunol. 2004 May 1;172(9):5154-7 - PubMed
  119. J Exp Med. 2011 Jan 17;208(1):13-21 - PubMed
  120. Blood. 2010 Nov 11;116(19):3865-74 - PubMed
  121. Immunity. 2005 Mar;22(3):295-304 - PubMed
  122. Trends Immunol. 2007 Jun;28(6):252-9 - PubMed
  123. J Immunol. 2004 Feb 1;172(3):1455-62 - PubMed
  124. Nature. 2007 Jul 26;448(7152):484-487 - PubMed
  125. J Immunol. 2007 Jan 1;178(1):85-94 - PubMed
  126. Blood. 2001 May 15;97(10):3146-51 - PubMed
  127. Curr Opin Immunol. 2008 Jun;20(3):344-52 - PubMed
  128. Cytotherapy. 2010 Dec;12(8):1044-55 - PubMed
  129. Proc Natl Acad Sci U S A. 2011 Sep 6;108(36):14725-32 - PubMed
  130. J Immunol. 1989 Nov 15;143(10):3183-91 - PubMed
  131. Blood. 1995 Nov 1;86(9):3287-94 - PubMed
  132. Front Immunol. 2012 Nov 29;3:347 - PubMed
  133. J Exp Med. 2009 Jan 16;206(1):25-34 - PubMed
  134. Cancer J Sci Am. 2000 Feb;6 Suppl 1:S2-7 - PubMed
  135. J Immunol. 2013 May 1;190(9):4754-62 - PubMed
  136. Nature. 2009 Jan 29;457(7229):557-61 - PubMed
  137. Blood. 2011 Sep 22;118(12):3273-9 - PubMed
  138. N Engl J Med. 2011 Dec 1;365(22):2055-66 - PubMed
  139. Front Immunol. 2013 Oct 08;4:289 - PubMed
  140. Blood. 1990 Dec 15;76(12):2421-38 - PubMed
  141. Blood. 2005 Apr 15;105(8):3051-7 - PubMed
  142. J Immunol. 1999 Apr 15;162(8):4511-20 - PubMed
  143. Nat Rev Immunol. 2007 Apr;7(4):279-91 - PubMed
  144. Clin Cancer Res. 2009 Mar 15;15(6):2123-9 - PubMed
  145. Blood. 2006 Mar 15;107(6):2409-14 - PubMed
  146. Cytokine. 2006 Sep;35(5-6):229-34 - PubMed
  147. Trends Immunol. 2013 Jun;34(6):251-8 - PubMed
  148. Blood. 2010 Nov 11;116(19):3853-64 - PubMed
  149. Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3384-9 - PubMed
  150. Nat Immunol. 2008 May;9(5):503-10 - PubMed
  151. Immunol Rev. 2007 Dec;220:169-82 - PubMed
  152. J Immunol. 2005 Aug 15;175(4):2167-73 - PubMed
  153. Biol Blood Marrow Transplant. 2014 Apr;20(4):463-73 - PubMed
  154. Nature. 2013 Feb 21;494(7437):361-5 - PubMed
  155. Cancer Immunol Immunother. 2010 Nov;59(11):1739-44 - PubMed
  156. Eur J Immunol. 1975 Feb;5(2):112-7 - PubMed
  157. J Clin Invest. 2000 Jul;106(1):117-24 - PubMed
  158. PLoS One. 2011;6(9):e22842 - PubMed
  159. J Interferon Cytokine Res. 2001 Apr;21(4):257-63 - PubMed
  160. Clin Cancer Res. 2008 Jun 1;14(11):3462-9 - PubMed
  161. J Immunol. 2004 Feb 15;172(4):2048-58 - PubMed
  162. PLoS Pathog. 2008 Feb 8;4(2):e27 - PubMed

Publication Types

Grant support